Evidence map›Paper›PMID 29249046›Full record

ArticleTransgenic research2018

Generation of transgenic goats by pronuclear microinjection: a retrospective analysis of a commercial operation (1995-2012).

W Gavin, S Blash, N Buzzell, D Pollock, L Chen, N Hawkins, J Howe, K Miner, J Pollock, C Porter and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Transgenic research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Passive Immunity toPathogens & immunity · 2020
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

W GavinLFB USA, Inc., 175 Crossing Boulevard, Framingham, MA, 01702, USA.
S BlashLFB USA, Inc., 175 Crossing Boulevard, Framingham, MA, 01702, USA.
N BuzzellLFB USA, Inc., 175 Crossing Boulevard, Framingham, MA, 01702, USA. nathan.buzzell@lfb-usa.com.ORCID 0000-0003-0849-7907
D PollockLFB USA, Inc., 175 Crossing Boulevard, Framingham, MA, 01702, USA.
L ChenLFB USA, Inc., 175 Crossing Boulevard, Framingham, MA, 01702, USA.
N HawkinsLFB USA, Inc., 175 Crossing Boulevard, Framingham, MA, 01702, USA.
J HoweLFB USA, Inc., 175 Crossing Boulevard, Framingham, MA, 01702, USA.
K MinerLFB USA, Inc., 175 Crossing Boulevard, Framingham, MA, 01702, USA.
J PollockLFB USA, Inc., 175 Crossing Boulevard, Framingham, MA, 01702, USA.
C PorterLFB USA, Inc., 175 Crossing Boulevard, Framingham, MA, 01702, USA.
M SchofieldLFB USA, Inc., 175 Crossing Boulevard, Framingham, MA, 01702, USA.
Y EchelardLFB USA, Inc., 175 Crossing Boulevard, Framingham, MA, 01702, USA.
H MeadeLFB USA, Inc., 175 Crossing Boulevard, Framingham, MA, 01702, USA.
LFB (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Production of transgenic founder goats involves introducing and stably integrating an engineered piece of DNA into the genome of the animal. At LFB USA, the ultimate use of these transgenic goats is for the production of recombinant human protein therapeutics in the milk of these dairy animals. The transgene or construct typically links a milk protein specific promoter sequence, the coding sequence for the gene of interest, and the necessary downstream regulatory sequences thereby directing expression of the recombinant protein in the milk during the lactation period. Over the time period indicated (1995-2012), pronuclear microinjection was used in a number of programs to insert transgenes into 18,120, 1- or 2- cell stage fertilized embryos. These embryos were transferred into 4180 synchronized recipient females with 1934 (47%) recipients becoming pregnant, 2594 offspring generated, and a 109 (4.2%) of those offspring determined to be transgenic. Even with new and improving genome editing tools now available, pronuclear microinjection is still the predominant and proven technology used in this commercial setting supporting regulatory filings and market authorizations when producing founder transgenic animals with large transgenes (> 10 kb) such as those necessary for directing monoclonal antibody production in milk.

Indexed as

Animals, Genetically ModifiedAnimalsEmbryo Culture TechniquesFemaleGenetic EngineeringGoatsMaleMicroinjectionsPregnancyPregnancy RateRecombinant ProteinsRetrospective StudiesRecombinant ProteinsGoatMicroinjectionRecombinant therapeuticsTransgenic

Identifiers

PMID29249046
OpenAlexW2775808501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.